Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2014

View Archived Issues

FDA grants triheptanoin orphan drug status for GLUT-1 deficiency syndrome

Researchers use germline DNA gene editing to prevent muscular dystrophy in mice

Development of a receptor tyrosine kinase decoy as a potential anticancer therapy

Clenbuterol earns FDA orphan drug designation as adjunctive therapy for Pompe's disease

Papillary thyroid carcinoma predisposition linked to a mutation in the SRRM2 gene

IL28B gene polymorphisms examined in chronic hepatitis B

Triphase expands collaboration with Celgene

Ventana Medical Systems to develop companion diagnostics for ImmunoGen

New gene linked to Charcot-Marie-Tooth disease

Novartis reflects on accomplishments of third quarter 2014

Bristol-Myers Squibb reports new HIV integrase inhibitors

PATH reports on phase I/IIb study of ACE-527 ETEC vaccine

Osteros Biomedica begins phase I trial of MBC-11

Shire reports pipeline progress of third quarter 2014

Saniona acquires obesity candidate from NeuroSearch

Cara Therapeutics reports data from CR-845 trial

Dr. Falk Pharma enrolls first patients in phase III trial of LT-02

FDA grants accelerated approval to Trumenba for prevention of meningococcal meningitis B

FDA approves Xigduo XR for type 2 diabetes

FDA grants fast track designation to Novavax's H7N9 VLP vaccine candidate

Alkem and Georgetown University patent Flavivirus protease inhibitors

New LpxC inhibitors reported by Achaogen

GW Pharmaceuticals initiates phase II/III study of Epidiolex for Dravet syndrome

Roche patents new BTK inhibitors

Quanticel Pharmaceuticals presents new histone demethylase inhibitors

Imago Biosciences reports new KDM1A inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.